DEDICATED / HAIR RESEARCH
Copper Peptide Hair Growth and GHK-Cu: What the Studies Show
The single controlled human trial, the angiogenic mechanism, and the important caveat that the trial tested a combination formulation — not pure GHK-Cu.
Copper peptide hair growth: the controlled trial
Copper peptide hair growth claims rest mainly on one controlled human trial. In a 6-month study of 45 men with androgenetic alopecia (Norwood-Hamilton II–V), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide — marketed as ALAVAX — increased hair count by 52.6 (at 100 mg/mL) and 71.5 (at 50 mg/mL) versus 9.6 for placebo, a statistically significant difference (p < 0.05), with no adverse events in any group [4].
That is the strongest controlled human efficacy signal for a GHK-containing topical, and it is the right place to start any honest copper-peptide-for-hair discussion. It is also where the first caveat lives: the trial tested a 5-ALA + GHK combination, not pure GHK-Cu, so the hair-count gains cannot be assigned to the copper peptide alone.
Do copper peptides stimulate hair growth?
A 6-month RCT in 45 men with androgenetic alopecia found a 5-ALA + GHK complex increased hair count significantly versus placebo (gains of 52.6 and 71.5 vs 9.6) [4]. Copper-peptide hair effects are attributed to angiogenesis and follicle support rather than DHT blockade, and the trial tested a combination formulation, not pure GHK-Cu.
Does Copper Peptide Regrow Hair? What the Trials Found
Does copper peptide regrow hair? The strongest controlled signal is the ALAVAX trial, where hair-count gains reached 52.6 and 71.5 over six months versus 9.6 for placebo [4]. That is a real, statistically significant result — but it is a single trial of a combination product (5-ALA plus GHK), and the literature has no equivalent large RCT of pure GHK-Cu for hair.
Mechanistically, the case is more developed than the clinical case. GHK-Cu raises VEGF in dermal fibroblasts and supports follicular angiogenesis and matrix turnover [6], and the Wnt/beta-catenin pathway associated with anagen entry is among its documented targets. So the direction of the evidence is favorable; the depth of the controlled human evidence is one combination trial.
Does copper peptide regrow hair?
The strongest controlled signal is the ALAVAX trial — hair-count gains of 52.6 and 71.5 versus 9.6 for placebo over six months [4]. Note it tested a 5-ALA + GHK combination, not pure GHK-Cu, so the regrowth signal cannot be attributed to the copper peptide alone. No large pure-GHK-Cu hair RCT exists.
Does copper peptide work for hair growth?
Preclinical work and the single human RCT support a hair-growth effect [4]. Mechanistically, GHK-Cu raises VEGF in dermal fibroblasts and supports follicular angiogenesis and matrix turnover [6]. The evidence direction is favorable, but the controlled human data is limited to one combination-formulation trial.
The mechanism is angiogenic, not anti-androgen
The most important sourcing distinction for copper-peptide hair claims is mechanism. GHK-Cu is not a DHT blocker. Its follicular activity is attributed to angiogenesis and follicle support — raised VEGF, follicular blood supply, and matrix turnover [6], plus Wnt/beta-catenin signaling associated with driving follicles into the active anagen growth phase.
That makes it mechanistically distinct from 5-alpha-reductase inhibitors, which work by lowering DHT. A copper peptide does not lower androgens; it supports the follicle's environment. For anyone evaluating claims, this matters: 'copper peptide as a natural DHT blocker' is a mechanism the GHK-Cu literature does not support.
Is copper a DHT blocker?
No. The copper-peptide hair mechanism is non-androgenic — GHK-Cu supports follicles through angiogenesis (raised VEGF and follicular blood supply) and matrix turnover [6], plus Wnt/beta-catenin anagen signaling, rather than by lowering DHT. It is mechanistically distinct from 5-alpha-reductase inhibitors, which act by reducing androgen levels.
How long does GHK-Cu take to regrow hair?
The 5-ALA + GHK trial measured outcomes over six months [4]. Popular guidance often cites roughly three months for meaningful change, but documented timelines in the literature are study- and formulation-specific, and the one controlled human dataset ran to six months rather than a shorter window.